Search Results for

Showing 1 - 9 of 9 results
  1. Spotlight on members: Spark

    Spotlight on members From hospital funding to FDA approval Spark Therapeutics develops gene therapy for inherited retinal blindness After over two decades of research and development in gene therapy, Katherine A. High, MD, co-founder, president and chief scientific officer of Spark Therapeutics, is breathing a big sigh of relief this fall. On Oct. 12, the Food and Drug Administration unanimously voted to approve voretigene neparvovec, Spark Therapeutics' gene therapy treatment for inherited b

  2. Housing and registration

    Registration and housing Registration Rates shown in U.S. dollars   Advance rate Onsite rate   Through July 6, 2018      After July 6, 2018 Regular attendee $495 $515 Student attendee*      $295 $315  *Students are undergraduate and graduate students, post-graduate fellows, medical students, optometry students and residents. Registration includes: 2.5 days of programming Coffee breaks, two lunches, one opening reception Champalimaud facility tour option (sign-up o

  3. Program

    Program Conference program The final conference program will include podium sessions, with opening and closing keynote lectures, a tour of the Champalimaud Centre for the Unknown, poster sessions and multiple opportunities for attendees to network. Speakers are international experts in oncogenesis and oncology, from the Champalimaud Centre for the Unknown and other ophthalmic centers around the globe.  Speakers Global Ocular Oncology Brenda Gallie, MD, FRCSC, SickKids Hospital & University

  4. Abstracts

    Abstracts Call for abstracts Abstract submission is open through Friday, March 23, 2018. The Ocular Oncogenesis and Oncology organizers seeks high-quality abstracts describing original, unpublished research results that contain a clear statement of hypothesis, an explanation of methods, a report of data that unequivocally test the hypothesis, and a brief discussion of their implications. Abstract reference tools Abstract Submission Policies and Procedures Abstract Submission FAQs Abstrac

  5. Abstracts

    Abstracts Call for abstracts Abstract submission is open through Friday, March 23, 2018. The Ocular Oncogenesis and Oncology organizers seeks high-quality abstracts describing original, unpublished research results that contain a clear statement of hypothesis, an explanation of methods, a report of data that unequivocally test the hypothesis, and a brief discussion of their implications. Abstract reference tools Abstract Submission Policies and Procedures Abstract Submission FAQs Abstrac

  6. Statement for the Use of Animals in Ophthalmic and Vision Research

    Statement for the Use of Animals in Ophthalmic and Vision Research Introduction Guidelines for the design of experiments Guidelines for the conduct of experiments Factors that relate specifically to the conduct of vision and ophthalmology experiments Investigators outside the United States Animal use guidelines Alternatives to animal research Animal use resources Organizations that promote proper and ethical use of laboratory animals Introduction Research in vision and ophthalmology i

  7. Registration

    NIH Updates for Human Subjects Research Administration

  8. About

    Online event: May 22, 2018